RENXF (Renalytix) Tariff Resilience Score: 6/10 (As of Jul. 08, 2026)


What is Renalytix Tariff Resilience Score?

Renalytix RENXF Tariff Resilience Score is 6 as of Jul. 08, 2026. The stock has 3 warning signs investors should review. Among 672 Healthcare Providers & Services companies, Renalytix ranks better than 83.48% on this metric.

Renalytix has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Renalytix has Renalytix PLC operates in the healthcare sector, which often benefits from tariff exemptions. The company has a global supply chain but primarily serves the US market. Historical tariff impacts have been minimal, and it has some pricing power in its niche market.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Renalytix might have Average Resilient.

Renalytix  (OTCPK:RENXF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Renalytix Tariff Resilience Score Related Terms

RENXF vs VEEV, BTSG, TEM: Tariff Resilience Score Comparison

For the Health Information Services subindustry, Renalytix's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renalytix Tariff Resilience Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Renalytix's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
Renalytix (RENXF) has a Tariff Resilience Score of 6 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Renalytix ranks #111 out of 672 companies in the Healthcare Providers & Services industry, placing it in the top 16.5%.
Is Renalytix's Tariff Resilience Score too high?
Renalytix's current Tariff Resilience Score is 6. Based on the distribution chart, Renalytix ranks #111 out of 672 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Renalytix's Tariff Resilience Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Renalytix ranks #111 out of 672 companies for Tariff Resilience Score. This places Renalytix in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Healthcare Providers & Services company?
A good Tariff Resilience Score depends on the Healthcare Providers & Services industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Renalytix's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Based on GuruFocus' analysis, Renalytix (RENXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.06, compared to a current price of $0.04 — trading 39.8% below its estimated fair value. The current Tariff Resilience Score is 6. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Renalytix (RENXF), the current Tariff Resilience Score is 6 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Renalytix Business Description

Other Exchanges RENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.